Heart Disease Clinical Trials in Tucson, AZ

43 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Prevail Global Study	N/A	Medtronic Vascular	3 mi
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System	N/A	Biosense Webster, Inc.	3 mi
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS	Phase 3	DalCor Pharmaceuticals	3 mi
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates	N/A	University of British Columbia	3 mi
The ENCIRCLE Trial	N/A	Edwards Lifesciences	3 mi
Omega-3D: Omega-3 for Diet-Driven Health Disparities	Phase 2	University of Arizona	3 mi
AltaValve Pivotal Trial	N/A	4C Medical Technologies, Inc.	3 mi
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System	N/A	Laplace Interventional, Inc	3 mi
Left vs Left Randomized Clinical Trial	N/A	Baylor College of Medicine	3 mi
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)	Phase 3	Intellia Therapeutics	3 mi
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery	Phase 3	Yale University	3 mi
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure	N/A	Nuwellis, Inc.	3 mi
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study	N/A	Ancora Heart, Inc.	3 mi
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy	Phase 2	Novo Nordisk A/S	3 mi
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin	Phase 3	AstraZeneca	3 mi
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis	Phase 2	Zomagen Biosciences Ltd.	3 mi
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events	Phase 3	Amgen	3 mi
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).	N/A	Mayra Guerrero	3 mi
CardioFocus HeartLight Post-Approval Study	N/A	CardioFocus	3 mi
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR	N/A	Edwards Lifesciences	3 mi
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction	Phase 3	Cytokinetics	3 mi
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy	Phase 4	Dennis M. McNamara, MD, MS	3 mi
Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day	—	Heart Rhythm Clinical and Research Solutions, LLC	3 mi
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II	N/A	Shockwave Medical, Inc.	3 mi
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF	Phase 2	Cytokinetics	3 mi
NobleStitch EL STITCH Trial is a PFO Comparative Trial	N/A	Nobles Medical Technologies II Inc	3 mi
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity	Phase 3	Amgen	3 mi
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)	Phase 3	Novartis Pharmaceuticals	3 mi
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events	N/A	Cleerly, Inc.	3 mi
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry	—	Universitätsklinikum Hamburg-Eppendorf	3 mi
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE	—	Medtronic Cardiovascular	3 mi
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes	Phase 4	VA Office of Research and Development	3 mi
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment	—	Children's Oncology Group	3 mi
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF	Phase 3	Tenax Therapeutics, Inc.	3 mi
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR	N/A	Cardiac Dimensions, Inc.	3 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	Phase 2/3	CSL Behring	3 mi
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)	—	Bristol-Myers Squibb	3 mi
The CONFORM Pivotal Trial	N/A	Conformal Medical, Inc	3 mi
Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)	N/A	University of Michigan	3 mi
An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System	N/A	HighLife SAS	3 mi
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial	N/A	Edwards Lifesciences	3 mi
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)	N/A	P+F Products + Features USA Inc.	3 mi
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study	N/A	W.L.Gore & Associates	3 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.